Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib

BACKGROUND: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We report herpes zoster (HZ) incidence and risk factors in the tofacitinib UC clinical program (up to 7.8 years). METHODS: Proportions and incidence rates (IRs; unique patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Winthrop, Kevin L, Vermeire, Séverine, Long, Millie D, Panés, Julian, Ng, Siew C, Kulisek, Nicole, Mundayat, Rajiv, Lawendy, Nervin, Vranic, Ivana, Modesto, Irene, Su, Chinyu, Melmed, Gil Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825290/
https://www.ncbi.nlm.nih.gov/pubmed/35648151
http://dx.doi.org/10.1093/ibd/izac063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825290/
https://www.ncbi.nlm.nih.gov/pubmed/35648151
http://dx.doi.org/10.1093/ibd/izac063

Ejemplares similares